Background—Insulin-like growth factor-1 (IGF-1) is recognized as an important regulator of cardiac structure and cardiomyocyte homeostasis. The prosurvival and antiapoptotic effects of IGF-1 have been investigated in vitro and in rodent models of myocardial infarction (MI). However, the clinical application of IGF-1 has been hampered by dose-dependent side effects both acutely and during chronic administration. We hypothesized that single, low-dose IGF-1 (LD-IGF-1) administered locally and early in the reperfusion phase after acute MI in a large animal model would avoid significant side effects but would have prosurvival effects that would manifest in long-term structural and functional improvement after MI treatment. Methods and Results—Fo...
Insulin-like growth factor 1 (IGF-1) signaling plays a role in the regulation of heart disease. Whil...
Insulin-like growth factors (IGF) I and II improve myocardial function after coronary occlusion in d...
Aims Strategies to prevent adverse left ventricular (LV) remodelling after myocardial infarction hav...
Background—Insulin-like growth factor-1 (IGF-1) is recognized as an important regulator of cardiac s...
Background-Insulin-like growth factor-1 (IGF-1) is recognized as an important regulator of cardiac s...
Background: Coronary artery disease is a global health concern in the present day with limited thera...
ObjectivesThe purpose of this study was to test the ability of insulin-like growth factor (IGF)-1/he...
Background Acute insulin-like growth factor-1 administration has been shown to have beneficial ef...
Background: Studies of insulin-like growth factor 1 (IGF-1) as a novel therapy for the treatment of ...
To determine whether IGF-1 opposes the stimulation of myocyte death in the surviving myocardium afte...
To determine whether IGF-1 opposes the stimulation of myo-cyte death in the surviving myocardium aft...
In an open-chest porcine model, we examined whether myocardial pharmacological conditioning at the t...
AbstractOBJECTIVESSupplemental myocardial hypertrophy induced by insulin-like growth factor (IGF)-1 ...
Angiogenesis factors are produced in response to hypoxic or ischemic insult at the site of pathology...
Introduction: Ischemia/reperfusion occurs in myocardial infarction, cardiac dysfunc...
Insulin-like growth factor 1 (IGF-1) signaling plays a role in the regulation of heart disease. Whil...
Insulin-like growth factors (IGF) I and II improve myocardial function after coronary occlusion in d...
Aims Strategies to prevent adverse left ventricular (LV) remodelling after myocardial infarction hav...
Background—Insulin-like growth factor-1 (IGF-1) is recognized as an important regulator of cardiac s...
Background-Insulin-like growth factor-1 (IGF-1) is recognized as an important regulator of cardiac s...
Background: Coronary artery disease is a global health concern in the present day with limited thera...
ObjectivesThe purpose of this study was to test the ability of insulin-like growth factor (IGF)-1/he...
Background Acute insulin-like growth factor-1 administration has been shown to have beneficial ef...
Background: Studies of insulin-like growth factor 1 (IGF-1) as a novel therapy for the treatment of ...
To determine whether IGF-1 opposes the stimulation of myocyte death in the surviving myocardium afte...
To determine whether IGF-1 opposes the stimulation of myo-cyte death in the surviving myocardium aft...
In an open-chest porcine model, we examined whether myocardial pharmacological conditioning at the t...
AbstractOBJECTIVESSupplemental myocardial hypertrophy induced by insulin-like growth factor (IGF)-1 ...
Angiogenesis factors are produced in response to hypoxic or ischemic insult at the site of pathology...
Introduction: Ischemia/reperfusion occurs in myocardial infarction, cardiac dysfunc...
Insulin-like growth factor 1 (IGF-1) signaling plays a role in the regulation of heart disease. Whil...
Insulin-like growth factors (IGF) I and II improve myocardial function after coronary occlusion in d...
Aims Strategies to prevent adverse left ventricular (LV) remodelling after myocardial infarction hav...